Anxiety in 2026: what changed

The 2020 FDA class-wide boxed warning on benzodiazepines continues to shape prescribing patterns, with growing emphasis on documented risk assessment and individualized tapering. Read on benzodiazepine benefits and risks.

DEA rulemaking on telemedicine prescribing of controlled substances remains in active iteration. Temporary extensions of pandemic-era flexibilities have been re-issued while a longer-term framework is finalized. See the telepsychiatry evidence summary.

CBT and SSRIs remain first-line in major guidelines. Reviews of the inhibitory learning framework for exposure therapy continue to refine protocol design choices, including expectancy violation, exposure variability, and removal of safety behaviors. Read the exposure therapy summary.

Mindfulness research continues to distinguish between structured eight-week MBSR and MBCT and shorter app-based programs, with smaller and more heterogeneous effects for the app-based literature. See the mindfulness evidence summary.

Workforce shortage areas remain concentrated in rural counties. Telepsychiatry has materially expanded the catchment of subspecialty care but is constrained by state licensure rules. See the rural-urban anxiety access brief and the state data directory.

In-network insurance acceptance among psychiatrists continues to lag most other specialties, which shifts cost to patients and shapes who is able to maintain medication management over time. Read on psychiatrist insurance acceptance.

No current ongoing U.S. survey replicates the full NCS-R diagnostic interview. Symptom-level series from CDC Household Pulse, NHIS, and BRFSS remain the most frequently cited population-level signals, and are clearly different anchors from disorder-level prevalence. See methods.